FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011205514> ?p ?o ?g. }

• W3011205514 endingPage "1149" @default.
• W3011205514 startingPage "1142" @default.
• W3011205514 abstract "Background and Purpose- EG-1962 is a sustained release formulation of nimodipine administered via external ventricular drain in patients with aneurysmal subarachnoid hemorrhage. A randomized, open-label, phase 1/2a, dose-escalation study provided impetus for this study to evaluate efficacy and safety of a single intraventricular 600 mg dose of EG-1962 to patients with aneurysmal subarachnoid hemorrhage, compared with standard of care oral nimodipine. Methods- Subjects were World Federation of Neurological Surgeons grades 2-4, modified Fisher grades 2-4 and had an external ventricular drain inserted as part of standard of care. The primary end point was the proportion of subjects with favorable outcome at day 90 after aneurysmal subarachnoid hemorrhage (extended Glasgow outcome scale 6-8). The proportion of subjects with favorable outcome at day 90 on the Montreal cognitive assessment, as well as the incidence of delayed cerebral ischemia and infarction, use of rescue therapy and safety were evaluated. Results- The study was halted by the independent data monitoring board after planned interim analysis of 210 subjects (289 randomized) with day 90 outcome found the study was unlikely to achieve its primary end point. After day 90 follow-up of all subjects, the proportion with favorable outcome on the extended Glasgow outcome scale was 45% (65/144) in the EG-1962 and 42% (62/145) in the placebo group (risk ratio, 1.01 [95% CI, 0.83-1.22], P=0.95). Consistent with its mechanism of action, EG-1962 significantly reduced vasospasm (50% [69/138] EG-1962 versus 63% [91/144], P=0.025) and hypotension (7% [9/138] versus 10% [14/144]). Analysis of prespecified subject strata suggested potential efficacy in World Federation of Neurological Surgeons 3-4 subjects (46% [32/69] EG-1962 versus 32% [24/75] placebo, odds ratio, 1.22 [95% CI, 0.94-1.58], P=0.13). No safety concerns were identified that halted the study or that preclude further development. Conclusions- There was no significant increase in favorable outcome for EG-1962 compared with standard of care in the overall study population. The safety profile was acceptable. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT02790632." @default.
• W3011205514 created "2020-03-23" @default.
• W3011205514 creator A5000156377 @default.
• W3011205514 creator A5000492857 @default.
• W3011205514 creator A5001908694 @default.
• W3011205514 creator A5003394099 @default.
• W3011205514 creator A5005432869 @default.
• W3011205514 creator A5006454522 @default.
• W3011205514 creator A5007168072 @default.
• W3011205514 creator A5008385581 @default.
• W3011205514 creator A5010715194 @default.
• W3011205514 creator A5012208611 @default.
• W3011205514 creator A5013728270 @default.
• W3011205514 creator A5014073957 @default.
• W3011205514 creator A5014149325 @default.
• W3011205514 creator A5015037794 @default.
• W3011205514 creator A5016562960 @default.
• W3011205514 creator A5016797598 @default.
• W3011205514 creator A5018029238 @default.
• W3011205514 creator A5018214563 @default.
• W3011205514 creator A5018453143 @default.
• W3011205514 creator A5018736336 @default.
• W3011205514 creator A5018865288 @default.
• W3011205514 creator A5019068952 @default.
• W3011205514 creator A5020463497 @default.
• W3011205514 creator A5022500290 @default.
• W3011205514 creator A5023277940 @default.
• W3011205514 creator A5024653973 @default.
• W3011205514 creator A5026868894 @default.
• W3011205514 creator A5027934124 @default.
• W3011205514 creator A5031270256 @default.
• W3011205514 creator A5033410175 @default.
• W3011205514 creator A5035830536 @default.
• W3011205514 creator A5036019319 @default.
• W3011205514 creator A5038958115 @default.
• W3011205514 creator A5038980182 @default.
• W3011205514 creator A5039539375 @default.
• W3011205514 creator A5041533304 @default.
• W3011205514 creator A5044867718 @default.
• W3011205514 creator A5044984785 @default.
• W3011205514 creator A5045468097 @default.
• W3011205514 creator A5046264726 @default.
• W3011205514 creator A5046813159 @default.
• W3011205514 creator A5048916190 @default.
• W3011205514 creator A5049222047 @default.
• W3011205514 creator A5049245761 @default.
• W3011205514 creator A5050795619 @default.
• W3011205514 creator A5051917683 @default.
• W3011205514 creator A5052793850 @default.
• W3011205514 creator A5053607760 @default.
• W3011205514 creator A5055628544 @default.
• W3011205514 creator A5060454556 @default.
• W3011205514 creator A5061484429 @default.
• W3011205514 creator A5061548587 @default.
• W3011205514 creator A5062595802 @default.
• W3011205514 creator A5063250341 @default.
• W3011205514 creator A5064250101 @default.
• W3011205514 creator A5064422913 @default.
• W3011205514 creator A5064696586 @default.
• W3011205514 creator A5065549183 @default.
• W3011205514 creator A5067606548 @default.
• W3011205514 creator A5067928315 @default.
• W3011205514 creator A5068022071 @default.
• W3011205514 creator A5068530075 @default.
• W3011205514 creator A5070106030 @default.
• W3011205514 creator A5070619742 @default.
• W3011205514 creator A5070912963 @default.
• W3011205514 creator A5070923679 @default.
• W3011205514 creator A5071706970 @default.
• W3011205514 creator A5072272174 @default.
• W3011205514 creator A5072833141 @default.
• W3011205514 creator A5073727333 @default.
• W3011205514 creator A5073809058 @default.
• W3011205514 creator A5073886735 @default.
• W3011205514 creator A5074275808 @default.
• W3011205514 creator A5075408324 @default.
• W3011205514 creator A5076135151 @default.
• W3011205514 creator A5076268338 @default.
• W3011205514 creator A5078165592 @default.
• W3011205514 creator A5078961564 @default.
• W3011205514 creator A5083545843 @default.
• W3011205514 creator A5083801559 @default.
• W3011205514 creator A5084474994 @default.
• W3011205514 creator A5084635207 @default.
• W3011205514 creator A5085592232 @default.
• W3011205514 creator A5085943949 @default.
• W3011205514 creator A5088068783 @default.
• W3011205514 creator A5089032910 @default.
• W3011205514 creator A5089497208 @default.
• W3011205514 creator A5089515314 @default.
• W3011205514 creator A5090506665 @default.
• W3011205514 date "2020-04-01" @default.
• W3011205514 modified "2023-10-13" @default.
• W3011205514 title "Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage" @default.
• W3011205514 cites W1574261673 @default.
• W3011205514 cites W1604952032 @default.
• W3011205514 cites W1981291188 @default.
• W3011205514 cites W1995517777 @default.

• next